Published in Vaccine Weekly, September 6th, 2006
According to a study from England, "Intravenous delivery of adenovirus vectors requires that the virus is not inactivated in the bloodstream. Serum neutralizing activity is well documented, but we show that type 5 adenovirus also interacts with human blood cells."
"Over 90% of a typical virus dose binds to human (but not murine) erythrocytes ex vivo, and samples from a patient administered adenovirus in a clinical trial showed that over 98% of viral DNA in the blood was cell associated," said Mark Lyons at the University of Oxford and collaborators in England. "In...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly